他克莫司聯合糖皮質激素治療難治性腎病綜合征的效果評价
|
摘要
目的研究他克莫司联合糖皮质激素治疗难治性肾病综合征的效果。方法采用回顾性分析法,选取2016年5月—2018年1月期间在该院接受治疗的74例难治性肾病综合征患者的临床资料进行研究,随机将患者分为两组:观察组(37例)和对照组(37例)。对照组采用糖皮质激素治疗,观察组在对照组治疗的基础上加用他克莫司进行联合治疗。观察两组患者临床指标、治疗效果和不良反应情况。结果治疗后,观察组患者尿蛋白(1.5±0.9)、(t=7.686 2),血清蛋白(38.4±5.3)、(t=7.826 3),TG(1.2±0.4)、(t=15.051 4),TC(2.2±1.0)、(t=9.032 4),SCr(65.3±15.6)、(t=5.595 4)各指标变化情况明显高于对照组,差异有统计学意义(P<0.05);观察组治疗总有效率为94.6%,明显高于对照组73.0%治疗总有效率,差异有统计学意义(χ~2=4.873 7,P<0.05);观察组总不良反应率为8.1%,显著低于对照组29.7%的不良反应率,差异有统计学意义(χ~2=4.316 7,P<0.05)。结论他克莫司联合糖皮质激素治疗难治性肾病综合征具有较好的效果,有效改善患者症状,不良反应少,安全性高。
Objective To study the effect of tacrolimus combined with glucocorticoid in treatment of refractory nephrotic syndrome. Methods The clinical data of 74 cases of patients with refractory nephrotic syndrome treated in our hospital from May 2016 to January 2018 were studied, and the patients were randomly divided into two groups with 37 cases in each, the control group were treated with glucocorticoid, while the observation group were treated with tacrolimus on the basis of the control group, and the clinical indicators, treatment effect and adverse reactions of the two groups were observed. Results After treatment, the urine protein(1.5 ±0.9),(t=7.686 2), serum albumin(38.4±5.3),(t=7.826 3),TG(1.2±0.4),(t=15.051 4),TC(2.2±1.0),(t=9.032 4),SCr(65.3±15.6),(t=5.595 4) were obviously higher than those in the control group, with statistical significance(P<0.05), and the total treatment effective rate in the observation group was obviously higher than that in the control group(94.6% vs 73.0%), with statistical significance(χ~2=4.873 7,P<0.05), and the total adverse reaction rate in the observation group was obviously lower than that in the control group(8.1% vs29.7%), with statistical significance(χ~2=4.316 7,P<0.05). Conclusion The effect of tacrolimus combined with glucocorticoid in treatment of refractory nephrotic syndrome is better, which can effectively improve the symptoms with few adverse reactions and high safety.
Objective To study the effect of tacrolimus combined with glucocorticoid in treatment of refractory nephrotic syndrome. Methods The clinical data of 74 cases of patients with refractory nephrotic syndrome treated in our hospital from May 2016 to January 2018 were studied, and the patients were randomly divided into two groups with 37 cases in each, the control group were treated with glucocorticoid, while the observation group were treated with tacrolimus on the basis of the control group, and the clinical indicators, treatment effect and adverse reactions of the two groups were observed. Results After treatment, the urine protein(1.5 ±0.9),(t=7.686 2), serum albumin(38.4±5.3),(t=7.826 3),TG(1.2±0.4),(t=15.051 4),TC(2.2±1.0),(t=9.032 4),SCr(65.3±15.6),(t=5.595 4) were obviously higher than those in the control group, with statistical significance(P<0.05), and the total treatment effective rate in the observation group was obviously higher than that in the control group(94.6% vs 73.0%), with statistical significance(χ~2=4.873 7,P<0.05), and the total adverse reaction rate in the observation group was obviously lower than that in the control group(8.1% vs29.7%), with statistical significance(χ~2=4.316 7,P<0.05). Conclusion The effect of tacrolimus combined with glucocorticoid in treatment of refractory nephrotic syndrome is better, which can effectively improve the symptoms with few adverse reactions and high safety.
引文
[1]范学礼.来氟米特联合糖皮质激素治疗难治性肾病综合征的效果分析[J].河南医学研究,2016(6):1088-1089.
[2]李平.他克莫司联合糖皮质激素治疗难治性肾病综合征临床效果观察[J].医学理论与实践,2018(11):1621-1622.
[3]刘月侠,吕鸿.来氟米特联合糖皮质激素治疗难治性肾病综合征的疗效分析[J].河北医药,2015(6):896-897.
[4]王春霞.他克莫司联合糖皮质激素治疗难治性肾病综合征的效果观察[J].临床合理用药杂志,2018(2):12-13.
[5]李学玲.他克莫司联合糖皮质激素治疗难治性肾病综合征的疗效分析[J].中国医药指南,2018(7):47-48.
[6]王杰,申兰雨,郭芳惠,等.他克莫司联合糖皮质激素治疗难治性肾病综合征的临床观察[J].中国保健营养,2018(5):84.
[7]杨艳.他克莫司联合糖皮质激素治疗难治性肾病综合征的临床观察[J].医学理论与实践,2017(17):2568-2569.
[8]李保俊.探讨他克莫司与糖皮质激素联合治疗难治性肾病综合征的疗效[J].临床医药文献电子杂志,2017(73):14423-14424.
[9]蒋慧生.糖皮质激素联合他克莫司治疗难治性肾病综合征的效果研究[J].东方食疗与保健,2017(7):102.
[10]刘艺.雷公藤多苷联合糖皮质激素对难治性肾病综合征的疗效观察[J].世界临床医学,2017(12):107,111.
[2]李平.他克莫司联合糖皮质激素治疗难治性肾病综合征临床效果观察[J].医学理论与实践,2018(11):1621-1622.
[3]刘月侠,吕鸿.来氟米特联合糖皮质激素治疗难治性肾病综合征的疗效分析[J].河北医药,2015(6):896-897.
[4]王春霞.他克莫司联合糖皮质激素治疗难治性肾病综合征的效果观察[J].临床合理用药杂志,2018(2):12-13.
[5]李学玲.他克莫司联合糖皮质激素治疗难治性肾病综合征的疗效分析[J].中国医药指南,2018(7):47-48.
[6]王杰,申兰雨,郭芳惠,等.他克莫司联合糖皮质激素治疗难治性肾病综合征的临床观察[J].中国保健营养,2018(5):84.
[7]杨艳.他克莫司联合糖皮质激素治疗难治性肾病综合征的临床观察[J].医学理论与实践,2017(17):2568-2569.
[8]李保俊.探讨他克莫司与糖皮质激素联合治疗难治性肾病综合征的疗效[J].临床医药文献电子杂志,2017(73):14423-14424.
[9]蒋慧生.糖皮质激素联合他克莫司治疗难治性肾病综合征的效果研究[J].东方食疗与保健,2017(7):102.
[10]刘艺.雷公藤多苷联合糖皮质激素对难治性肾病综合征的疗效观察[J].世界临床医学,2017(12):107,111.